Central Mechanisms in Speech Motor Control Studied With H215O PET
Official Title †
Multimodal Studies of Language Production and Comprehension in Normal Volunteers and Patients With Neurologically-Based Language Impairments
Positron Emission Tomography (PET) is a technique used to investigate the functional
activity of the brain. The PET technique allows doctors to study the normal biochemical and
metabolic processes of the central nervous system of normal individuals and patients with
neurologic illnesses without physical / structural damage to the brain. Radioactive water
H215O in PET scans permits good visualization of areas of the brain related to speech.
Most of the PET scan studies conducted have concentrated on learning about how language is
formed and decoded. Few studies have been conducted on speech production. This study aims to
use radioactive water (H215O) and Positron Emission Tomography (PET scan) to measure blood
flow to different areas of the brain in order to better understand the mechanisms involved
in speech motor control.
When a region of the brain is active, it uses more fuel in the form of oxygen and sugar
(glucose). As the brain uses more fuel it produces more waste products, carbon dioxide and
water. Blood carries fuel to the brain and waste products away from the brain. As brain
activity increases blood flow to and from the area of activity increases also. Knowing these
facts, researchers can use radioactive chemicals (H215O) and PET scans to observe what areas
of the brain are receiving more blood flow.
Researchers will ask patients to perform tasks that will affect speech, voice, and language.
At the same time patients will undergo a PET scan. The tasks are designed to help
researchers observe the blood flow to brain areas associated with voicebox (laryngeal)
functions, movement of muscles in the jaw, tongue, and mouth, and other aspects of motor
Special studies will be conducted to evaluate how certain therapies and tasks can draw out
symptoms in illnesses in which speech and language are affected. Results of these tests will
be used in other studies to evaluate the neurologic mechanisms of diseases like Tourette's
syndrome and parkinson's disease.
The primary objective of this protocol is to use multimodal neuroimaging combining
complementary electrophysiological and hemodynamic methods to characterize brain-language
relationships in healthy subjects and those with neurological disorders that affect speech
and language. A secondary objective is to utilize these findings to develop evaluation
measures for future treatment studies.
We will focus on four neurological disorders that affect language processing post-stroke
aphasia, traumatic brain injury, epilepsy and developmental stuttering. Each constitutes a
significant clinical problem central to the NIDCD s mission. These disorders can impair
language at several levels - from its elementary perceptual and motor features, the
peripheral building blocks of language, to higher levels of language formulation, including
word, sentence and narrative processing.
We will utilize a set of tasks designed to evaluate language at the levels at which clinical
pathology emerges. We will combine hemodynamic (functional MRI) and electrophysiological
(EEG, MEG) modalities to capitalize on the superior spatial resolution of the former and
temporal resolution of the latter methods. Whenever possible the same task paradigms are
used with both techniques. We will conduct crosssectional sub-studies, addressing specific
questions in each of the disorders of interest; we will also conduct longitudinal
sub-studies of recovery and neuroplastic reorganization in post-stroke aphasia.
Outcome measures include speech-language and psychological tests, measures of behavioral
performance during scanning and corresponding MRI, EEG and MEG data. Relationships between
these datasets will be evaluated using statistical analytic packages.
Study Type †
Study Design †
Primary Outcome Measure †
Secondary Outcome Measure †
Study Arms / Comparison Groups
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Status †
Estimated Enrollment †
Start Date †
April 28, 1992
October 6, 2016
Primary Completion Date
Eligibility Criteria †
- INCLUSION CRITERIA FOR ALL SUBJECTS:
Ages 18 to 85.
Ability to provide informed consent.
Must be a Native English speaker by age 2
SPECIFIC INCLUSION CRITERIA FOR SELECTED GROUPS OF HEALTHY VOLUNTEERS:
Have had training and experience in creative writing
Have had training and experience in vocal or instrumental music
Have had training and experience in visual arts
SPECIFIC INCLUSION CRITERIA FOR POST-STROKE APHASIA SUBJECTS:
Had sensorimotor and language deficits following ischemic infarcts.
Had stroke at least two weeks ago.
SPECIFIC INCLUSION CRITERIA FOR TRAUMATIC BRAIN INJURY SUBJECTS:
Diagnosis of TBI
At least one month post-injury
SPECIFIC INCLUSION CRITERIA FOR STUTTERING SUBJECTS:
History of developmental stuttering with symptoms of dysfluency presenting before the age
If recovered, history documented by school or medical records.
SPECIFIC INCLUSION CRITERIA FOR EPILEPSY SUBJECTS:
Ages 18 to 55 years.
Failure of seizures to respond to adequate therapy with at least two standard
Willingness to be considered for surgery
Fluency in English. Non-native speakers may be included if their fluency is equivalent to
that of a native speaker.
Must have localization-related epilepsy
Must be currently enrolled in Protocol 08-N-0161 to participate in this study
EXCLUSION CRITERIA FOR ALL SUBJECTS:
Past or present major medical or psychiatric illnesses (DSM-IV criteria) except Post
Traumatic Stress Disorder (PTSD) in TBI subjects an anxiety disorder in stuttering
Significant abnormalities on the general physical examination unrelated to the stroke or
Unable to undergo MRI studies due to pacemakers, aneurysm clips, cochlear implants,
shrapnel fragments or a significant history of exposure to small metallic objects which
might have become lodged in the tissues of the head or neck or who require hearing aids.
Subjects who are pregnant are excluded from the PET and MRI tests in this study.
Subjects who are lactating are excluded from the PET tests.
Subjects who have or are found to have significant visual agnosia.
Subjects who cannot provide informed consent.
SPECIFIC EXCLUSION CRITERIA FOR POST-STROKE APHASIA SUBJECTS:
More than two prior strokes
Concurrent diagnoses of neurodegenerative disorders or vascular dementia
Comprehension Aphasia Quotient (AQ) of less than 4 on the Western Aphasia Battery (WAB)
SPECIFIC EXCLUSION CRITERIA FOR TRAUMATIC BRAIN INJURY SUBJECTS:
For military subjects: Positive screen for Acinetobacter baumannii-calcoaceticus complex
(ABC) infection or colonization
Severe cognitive impairments as evidenced by scores of less than 7 on the Rancho Los
Amigos Scale of Cognitive Functioning and/or less than 76 on the Galveston Orientation and
For all subjects: Comprehension AQ of less than 4 on the WAB
A diagnosis of PTSD, which is almost always found in TBI subjects recruited from the
military, will not disquality TBI subjects from participation.
SPECIFIC EXCLUSION CRITERIA FOR STUTTERING SUBJECTS:
Structural abnormalities on standard clinical (MPRAGE, T2-weighted) MRI scans studies
A diagnosis of anxiety dirorder will not disqualify stuttering subjects from participation
SPECIFIC EXCLUSION CRITERIA FOR EPILEPSY SUBJECTS:
Claustrophobia or anxiety disorders that could be exacerbated by the MRI Scanner
Subjects with neurological disorders, in addition to epilepsy such as, stroke, Parkinson s
disease), or who have psychiatric diagnoses (, such as, obsessive-compulsive disorder)
Patients on Phenobarbital or chronic Benxodiazepines
18 Years - 85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Location Countries †
NCT ID †
Secondary IDs ††
Study Sponsor †
National Institute on Deafness and Other Communication Disorders (NIDCD)
Principal Investigator: Allen R Braun, M.D., National Institute on Deafness and Other Communication Disorders (NIDCD)
Information Provided By
October 6, 2016
First Received Date †
November 3, 1999
Last Updated Date
April 19, 2017
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.